McKesson Growth at Risk as Drugmakers Curb Price Increases
- White House demands for prices to come down could pose threat
- If drug prices sink, so will payments the company counts on
This article is for subscribers only.
Drugmakers are tapping the brakes on price increases. For McKesson Corp. investors, that could mean lost sales.
The drug distributor earns a percentage of a given medication’s list price. If pharmaceutical companies continue to put off plans to raise prices amid pressure from the Trump administration, that could threaten San Francisco-based McKesson’s bottom line.